Navigation Links
Quit-Smoking Drug May Raise Suicide Risk
Date:2/1/2008

FDA asks maker of Chantix to revise warning on product label

FRIDAY, Feb. 1 (HealthDay News) -- There's increasing evidence that the smoking-cessation drug Chantix is linked to serious "neuropsychiatric" side effects, including agitation, depressed mood and even suicide, U.S. health officials said Friday.

The U.S. Food and Drug Administration has asked Chantix's manufacturer, Pfizer Inc., to make the warning about these potential problems more prominent on prescribing information and on the drug's label. The agency is also working with Pfizer to produce a Medication Guide for patients, officials said.

"We have become increasingly concerned as we have seen a number of compelling cases that truly look as if they are the result of exposure to the drug and not to other causes," Dr. Bob Rappaport, director of the FDA's Division of Anesthesia, Analgesia and Rheumatology Products, said during an afternoon teleconference.

"These cases involve abnormal behaviors, changes in mood, and suicidal ideation and suicide," Rappaport said.

The FDA knows of 491 cases of suicidal behavior associated with Chantix, said Dr. Celia Winchell, a team leader in the FDA's Division of Anesthesia, Analgesia and Rheumatology Products.

"Of these, 420 are from the United States," Winchell said. "There are 39 that involve completed suicides, 34 in the United States."

According to Pfizer, 5 million patients have taken Chantix, whose generic name is varenicline.

Friday's warning follows a Nov. 20 FDA statement that the agency was "evaluating post-marketing adverse event reports on Chantix related to changes in behavior, agitation, depressed mood, suicidal ideation, and actual suicidal behavior."

At that time, Pfizer said there had never been a cause-and-effect relationship shown between Chantix and these symptoms. The company also said that part of the problem may be due to nicotine withdrawal.

Last month, Pfizer agreed, after consulting with the FDA, to update packages of Chantix sold in the United States to more prominently display a warning that users should be monitored for suicidal behavior, depressed mood, and other mental health symptoms.

The FDA approved Chantix in May 2006 as a smoking-cessation drug. It acts in areas of the brain affected by nicotine and may ease withdrawal symptoms and block the effects of nicotine if users resume smoking.

On Friday, FDA officials advised patients to tell their doctor about any history of psychiatric illness before starting Chantix. The drug can cause current psychiatric illness to get worse even if it is under control. Chantix may also cause the recurrence of an old psychiatric illness, the officials warned.

Patients should also report changes in mood and behavior to their doctor. Symptoms to look out for include anxiety, nervousness, tension, depressed mood, unusual behaviors and thinking about or attempting suicide, the FDA officials said.

In most cases, these symptoms developed while taking Chantix, but they can also appear after stopping the drug, the officials noted.

"We are continuing with the review process over the next several months as we try to pin down to what extent these problems are being seen with Chantix," Rappaport said.

Vivid, unusual, or strange dreams may occur while taking the drug. Patients may also experience impaired ability to drive or operate heavy machinery, the officials said.

More information

For more on quitting smoking, visit Smokefree.gov.



SOURCES: Feb. 1, 2008, teleconference with Bob Rappaport, M.D., director, and Celia Winchell, M.D., team leader, Division of Anesthesia, Analgesia and Rheumatology Products, Office of Drug Evaluation II, Center for Drug Evaluation and Research, U.S. Food and Drug Administration


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Health Organizations Join Forces Around Quit-Smoking Help
2. New review suggests caution on drugs to raise good cholesterol
3. Antioxidant Supplements May Raise Womens Skin Cancer Risk
4. Acrylamide Wont Raise Breast Cancer Risk
5. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
6. BlueCare(R) Family Plan, a HUSKY Health Plan from Anthem Blue Cross and Blue Shield in Connecticut, Raises Awareness, Funds and Diapers for New Haven Diaper Bank
7. Mercedes-Benz Special Edition C350 Sport Sedan to Raise $1 Million for Saks Fifth Avenues KEY TO THE CURE
8. Care reforms raise concerns over patient access to GP services
9. The Will and Jada Smith Family Foundation and Maybelline Join Forces With the Lupus Foundation of America for a Star-studded Gala to Raise Awareness for Lupus
10. Computer models help raise the bar for sporting achievement
11. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Quit-Smoking Drug May Raise Suicide Risk
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which is ... in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) ... website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, SEO ... already in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... ... 23, 2017 , ... The Center for Autism and Related ... Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The ... see films in an environment that accommodates their unique needs. , Launched in ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  As National ... In addition, the Company is helping people live ... its customized prescription savings programs in all 50 ... Prescription Assistance Program  and  California Prescription Assistance Program ... from Columbia University for nutritious eating ...
(Date:2/23/2017)... -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine ... develop and market advanced products and therapies for the ... Dental sectors of healthcare, today announced its record results ... 31, 2016. Full Year 2016 Highlights are: ... over full year 2015 revenue ...
(Date:2/23/2017)... Feb. 23, 2017 LG Innotek today announced that the ... applications. As its sterilization performance is 1.5 times higher than the ... ultraviolet rays in the range of 200 -- 280nm, allowing it to ... by destroying their DNA. LG Innotek,s product emits UV in the ... ...
Breaking Medicine Technology: